As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Initial Feasibility Study to Treat Pancreatic Cancer With a Planar LDR Source
This is a feasibility study to determine the safety and efficacy of a new brachytherapy device that provides unidirectional radiation which utilizes active components (Palladium-103) of standard devices in a novel configuration. This pilot study may benefit pancreatic cancer patients by reducing the radiation dose to adjacent critical structures, while giving a therapeutic dose to diseased tissue, such as at a surgical margin. The appropriate dose and local control rate will be recorded the primary endpoint in order to provide an efficacy assessment.
In order to participate you must meet the following criteria:
- Are capable of undergoing anesthesia.
- Have been selected to undergo Whipple procedure.
- Do not have metastatic disease.
- Have suspected R0 or R1 margins.
- Have no prior radiation therapy to the region for separate cancer.
- Have a confirmed diagnosis of borderline resectable or locally advanced pancreatic adenocarcinoma.
This is a partial list of elgibility requirements.